OnCo research pulse

Inhibrx claims first win for the long-sought OX40 target

2026-09-08T00:00:00Z

Responses in head and neck cancer, strongest in HPV-positive tumours, after 15 years of failed OX40 programmes at big pharma.

Read at STAT News on 2026-09-08; sentiment promising.

On OnCo: Head and neck squamous cell carcinoma, Immune checkpoint inhibitors

A breakthrough pancreatic cancer drug won approval. Patients still struggle to access it

2026-09-08T00:00:00Z

Insurance barriers after the daraxonrasib approval.

Read at STAT News on 2026-09-08; sentiment cautious.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma

Metabolic syndrome commonly develops in men on ADT plus ARPI

2026-09-08T00:00:00Z

About 40% within a year, per the reported analysis.

Read at Healio Hematology/Oncology on 2026-09-08; sentiment cautious.

On OnCo: Androgen deprivation & AR pathway inhibitors, Prostate cancer, Cardio-oncology

Azacitidine/venetoclax boosts event-free survival in induction-eligible AML

2026-09-08T00:00:00Z

Coverage of the NEJM head-to-head with intensive chemotherapy.

Read at CancerNetwork (ONCOLOGY) on 2026-09-08; sentiment promising.

On OnCo: Azacitidine, Venetoclax, Acute myeloid leukaemia

Alcohol-attributable cancer mortality has doubled in the US since 1990

2026-09-08T00:00:00Z

Prevention story with policy implications.

Read at CancerNetwork (ONCOLOGY) on 2026-09-08; sentiment negative.

On OnCo: Chemoprevention & risk-reducing surgery

DeLLphi-305: durvalumab + tarlatamab meets OS in first-line maintenance ES-SCLC

2026-09-08T00:00:00Z

563 patients; first phase 3 T-cell engager OS win in first-line maintenance small-cell lung cancer; numbers pending a congress.

Read at OncoDaily on 2026-09-08; sentiment promising.

On OnCo: Tarlatamab, Durvalumab, DeLLphi-305, Small-cell lung cancer, T-cell engagers (bispecific)

Arlocabtagene autoleucel meets primary endpoint in the QUINTESSENTIAL myeloma trial

2026-09-08T00:00:00Z

The GPRC5D CAR-T advances toward filing.

Read at OncoDaily on 2026-09-08; sentiment promising.

On OnCo: GPRC5D, CAR-T cell therapy, Multiple myeloma

KEYLYNK-001: pembrolizumab ± olaparib maintenance in BRCA-wild-type ovarian cancer

2026-09-07T00:00:00Z

Vergote et al., 7 September: the immunotherapy plus PARP maintenance question in first line.

Read at The Lancet Oncology on 2026-09-07; sentiment neutral.

On OnCo: Pembrolizumab, Olaparib, Ovarian cancer, PARP inhibitors

Lessons from one of the first randomised trials of AI in medicine

2026-09-07T00:00:00Z

Lång, 7 September: what the MASAI mammography-AI trial taught about running AI trials.

Read at Nature Medicine on 2026-09-07; sentiment promising.

On OnCo: AI in radiology, Mammography & tomosynthesis

Oncology dealmaking is becoming more surgical

2026-09-07T00:00:00Z

Buyers target specific modalities and assets rather than platforms.

Read at Evaluate Vantage on 2026-09-07; sentiment neutral.

On OnCo: Antibody-drug conjugate (ADC), Radioligand therapy (beta emitters)

Six first-in-class approvals in August, including Etcamah

2026-09-05T00:00:00Z

Camizestrant counted among August's first-in-class approvals.

Read at BioCentury on 2026-09-05; sentiment neutral.

On OnCo: Camizestrant

Accelerated approval: camizestrant + CDK4/6 inhibitor for ESR1-mutated HR+/HER2- breast cancer

2026-09-04T00:00:00Z

Etcamah approved 4 September after a 6-3 negative advisory vote, on SERENA-6 ctDNA-guided switching data.

Read at FDA Oncology Approvals (OCE) & Novel Drug Approvals on 2026-09-04; sentiment promising.

On OnCo: Camizestrant, SERENA-6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer

Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations

2026-09-04T00:00:00Z

Camizestrant plus a CDK4/6 inhibitor, accelerated approval.

Read at Healio Hematology/Oncology on 2026-09-04; sentiment promising.

On OnCo: Camizestrant, HR-positive / HER2-negative breast cancer

Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodelling

2026-09-04T00:00:00Z

Stroma as a therapeutic target after chemotherapy.

Read at bioRxiv on 2026-09-04; sentiment neutral.

On OnCo: FAP, Epithelial-mesenchymal transition & drug efflux

Daraxonrasib for previously treated RAS-mutant NSCLC

2026-09-03T00:00:00Z

Arbour et al., 3 September: the pan-RAS inhibitor shows activity beyond pancreatic cancer.

Read at New England Journal of Medicine on 2026-09-03; sentiment promising.

On OnCo: Daraxonrasib, KRAS, Non-small-cell lung cancer

Azacitidine-venetoclax or induction chemotherapy for AML

2026-09-03T00:00:00Z

Fathi et al., 3 September: the chemotherapy-free doublet compared head to head with 7+3 in fit patients, with an accompanying editorial.

Read at New England Journal of Medicine on 2026-09-03; sentiment promising.

On OnCo: Azacitidine, Venetoclax, Acute myeloid leukaemia, VIALE-A

Molecularly guided therapy vs chemotherapy in cancer of unknown primary (CUPISCO)

2026-09-03T00:00:00Z

Krämer et al., 3 September: genomics-directed treatment tested in a randomised trial.

Read at Journal of Clinical Oncology on 2026-09-03; sentiment neutral.

On OnCo: Comprehensive genomic profiling, Companion diagnostics

Pan-RAS inhibitor shows activity in advanced lung cancer

2026-09-03T00:00:00Z

News digest, 3 September, on the NEJM daraxonrasib NSCLC data.

Read at Cancer Discovery on 2026-09-03; sentiment promising.

On OnCo: Daraxonrasib, KRAS, Non-small-cell lung cancer

Daraxonrasib exhibits 'encouraging signal' in RAS-mutant metastatic lung cancer

2026-09-03T00:00:00Z

The pancreatic drug's NEJM lung data.

Read at Healio Hematology/Oncology on 2026-09-03; sentiment promising.

On OnCo: Daraxonrasib, Non-small-cell lung cancer

DLL3 expression predicts response and long-term outcome in SCLC

2026-09-03T00:00:00Z

Biomarker work relevant to tarlatamab and DLL3 engagers.

Read at bioRxiv on 2026-09-03; sentiment neutral.

On OnCo: DLL3, Tarlatamab, Small-cell lung cancer

HARMONi: ivonescimab plus chemotherapy after EGFR-TKI failure

2026-09-01T00:00:00Z

Le et al.: the global phase 3 of the PD-1×VEGF bispecific in EGFR-mutant NSCLC, PFS positive with OS not statistically significant.

Read at The Lancet Oncology on 2026-09-01; sentiment cautious.

On OnCo: Ivonescimab, Non-small-cell lung cancer, EGFR, PD-1, VEGF / VEGFR

AI-based TIL quantification in TNBC: independent validation

2026-09-01T00:00:00Z

Dixon-Douglas et al. and a companion APHINITY analysis compare manual, digital, and AI TIL scoring.

Read at The Lancet Oncology on 2026-09-01; sentiment promising.

On OnCo: Tumour-infiltrating lymphocytes (TILs), Digital pathology & AI, Triple-negative breast cancer (TNBC), APHINITY

GETUG-AFU 18: dose-escalated radiotherapy with long-term ADT in high-risk prostate cancer

2026-09-01T00:00:00Z

Hennequin et al.: higher dose improves progression-free survival.

Read at The Lancet Oncology on 2026-09-01; sentiment promising.

On OnCo: IMRT / IGRT (modern external beam), Androgen deprivation & AR pathway inhibitors, Prostate cancer

SHR-A2102, a Nectin-4 ADC, in pretreated solid tumours (phase 1)

2026-09-01T00:00:00Z

Zhong et al.: a Chinese Nectin-4 ADC beyond urothelial cancer.

Read at The Lancet Oncology on 2026-09-01; sentiment neutral.

On OnCo: Nectin-4, Antibody-drug conjugate (ADC), Enfortumab vedotin

Ifebemtinib plus garsorasib in KRAS G12C colorectal cancer (phase 1b/2)

2026-09-01T00:00:00Z

Song et al.: a FAK inhibitor plus a G12C inhibitor, another route around the CRC feedback problem.

Read at The Lancet Oncology on 2026-09-01; sentiment promising.

On OnCo: KRAS, Colorectal cancer, KRAS & RAS inhibitors

NSABP B-59/GeparDouze: atezolizumab in early TNBC

2026-09-01T00:00:00Z

Loibl et al., 1 September: the randomised phase 3 of PD-L1 blockade in the curative setting.

Read at Nature Medicine on 2026-09-01; sentiment neutral.

On OnCo: Atezolizumab, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors, KEYNOTE-522

Tumour-secreted ADAMTSL4 activates latent TGFβ1 to drive cancer cachexia

2026-09-01T00:00:00Z

Machado et al., 1 September: a new mechanism behind the wasting that kills many patients.

Read at Cancer Discovery on 2026-09-01; sentiment promising.

On OnCo: Supportive Care & Survivorship

Long-read haplotype phasing as a missing layer of precision oncology

2026-09-01T00:00:00Z

Vo et al., 1 September: allelic configuration changes how some variants should be interpreted.

Read at Cancer Discovery on 2026-09-01; sentiment neutral.

On OnCo: Whole-exome & whole-genome sequencing, Comprehensive genomic profiling

ASCENT-04 exploratory analysis: sacituzumab govitecan + pembrolizumab improves PFS2

2026-09-01T00:00:00Z

Benefit of the ADC-immunotherapy first line carries into the next line in PD-L1+ TNBC.

Read at The ASCO Post on 2026-09-01; sentiment promising.

On OnCo: Sacituzumab govitecan, Pembrolizumab, ASCENT-04 / KEYNOTE-D19, Triple-negative breast cancer (TNBC), ADC + checkpoint inhibitor

Geriatric oncology at ASCO 2026: the next challenge is implementation

2026-09-01T00:00:00Z

Trials show assessment-guided care cuts toxicity; the field now has to deliver it routinely.

Read at The ASCO Post on 2026-09-01; sentiment neutral.

On OnCo: Geriatric assessment

MD Anderson president announces retirement

2026-09-01T00:00:00Z

Peter Pisters retiring; Jeffrey Lee named interim president.

Read at The ASCO Post on 2026-09-01; sentiment neutral.

On OnCo: MD Anderson Cancer Center

Long-course chemoradiotherapy shows early organ-preservation advantage in rectal cancer

2026-09-01T00:00:00Z

Extended treatment improves mesorectal-excision-free survival versus short course.

Read at The ASCO Post on 2026-09-01; sentiment promising.

On OnCo: Colorectal cancer, IMRT / IGRT (modern external beam)

Medicus Pharma secures worldwide rights to Pfizer's discontinued CD228 ADC

2026-09-01T00:00:00Z

A deal valued over $1 billion for a shelved programme, a sign of ADC demand.

Read at ADC Review on 2026-09-01; sentiment neutral.

On OnCo: Antibody-drug conjugate (ADC), Pfizer (incl. Seagen)

Radiopharmaceutical experts push the bounds of dosing

2026-08-31T00:00:00Z

Louise Emmett and others argue industry is too cautious on dosing frequency; kidney, liver, and marrow toxicity have already ended at least one company.

Read at STAT News on 2026-08-31; sentiment cautious.

On OnCo: Radioligand therapy (beta emitters), Targeted alpha therapy, Lutetium-177 vipivotide tetraxetan

After a rough stretch, mRNA gets a boost

2026-08-31T00:00:00Z

Politics and science collide as mRNA cancer vaccines regain momentum.

Read at STAT News on 2026-08-31; sentiment neutral.

On OnCo: Personalised neoantigen (mRNA) vaccines, Moderna, BioNTech

Pipeline Watch, August 2026: dealmaking accelerates

2026-08-31T00:00:00Z

Licensing, a pivotal lung readout, and Treg-directed conjugates.

Read at ADC Review on 2026-08-31; sentiment neutral.

On OnCo: Antibody-drug conjugate (ADC), Bispecific ADC

After CAR-T relapse in mantle cell lymphoma, a CD79b ADC produces durable remission

2026-08-31T00:00:00Z

Sequencing modalities in lymphoma.

Read at ADC Review on 2026-08-31; sentiment promising.

On OnCo: Antibody-drug conjugate (ADC), CAR-T cell therapy, Diffuse large B-cell lymphoma

LLM-assisted evidence audit of late-stage cancer incidence as a screening trial endpoint

2026-08-29T00:00:00Z

Directly relevant to the NHS-Galleri result and the FDA advisory committee.

Read at medRxiv on 2026-08-29; sentiment cautious.

On OnCo: Multi-cancer early detection (MCED), NHS-Galleri, Galleri, Stage shift

AEGEAN update: perioperative durvalumab in resectable NSCLC

2026-08-28T00:00:00Z

Heymach et al., 28 August: longer follow-up of the perioperative PD-L1 regimen.

Read at Journal of Clinical Oncology on 2026-08-28; sentiment promising.

On OnCo: Durvalumab, Non-small-cell lung cancer, Immune checkpoint inhibitors

Lymphodepletion mitigates anti-CAR immunity in paediatric brain tumours

2026-08-27T00:00:00Z

Clinical trial results on a practical barrier to repeat CAR-T dosing in glioma.

Read at medRxiv on 2026-08-27; sentiment promising.

On OnCo: CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), CAR-T cell therapy, Glioma & glioblastoma

Daraxonrasib approved for metastatic pancreatic adenocarcinoma

2026-08-26T00:00:00Z

First RAS inhibitor for pancreatic cancer, approved 26 August on RASolute 302.

Read at FDA Oncology Approvals (OCE) & Novel Drug Approvals on 2026-08-26; sentiment promising.

On OnCo: Daraxonrasib, RASolute 302, KRAS, Pancreatic ductal adenocarcinoma

ASCO living guideline: medical therapy for HR+/HER2- stage I-III breast cancer

2026-08-26T00:00:00Z

Caswell-Jin et al., 26 August: the current US recommendations in one document.

Read at Journal of Clinical Oncology on 2026-08-26; sentiment neutral.

On OnCo: HR-positive / HER2-negative breast cancer, Endocrine therapy (SERMs, AIs, SERDs), CDK4/6 inhibitors

Point-of-care breath VOC analysis for lung cancer screening: pilot

2026-08-26T00:00:00Z

A radical screening idea at feasibility stage.

Read at medRxiv on 2026-08-26; sentiment neutral.

On OnCo: Low-dose CT lung screening, Early Detection & Screening

Zanidatamab + tislelizumab for HER2+ gastric/GEJ/oesophageal adenocarcinoma

2026-08-25T00:00:00Z

Approved 25 August on HERIZON-GEA-01; a HER2 bispecific plus PD-1 in first line.

Read at FDA Oncology Approvals (OCE) & Novel Drug Approvals on 2026-08-25; sentiment promising.

On OnCo: Zanidatamab, Tislelizumab, HERIZON-GEA-01, Gastric & gastro-oesophageal junction cancer, Oesophageal cancer, HER2

Inside Moderna and Merck's cancer vaccine triumph

2026-08-24T00:00:00Z

The INTerpath-001 win and the algorithm behind neoantigen selection.

Read at STAT News on 2026-08-24; sentiment promising.

On OnCo: Intismeran autogene, INTerpath-001 (V940-001), Personalised neoantigen (mRNA) vaccines, Melanoma

Intercepting pancreatic cancer with a vaccine

2026-08-20T00:00:00Z

O'Leary, 20 August: research highlight on vaccination before invasive pancreatic cancer develops.

Read at Nature Medicine on 2026-08-20; sentiment promising.

On OnCo: Pancreatic ductal adenocarcinoma, Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines

OPTIMA: a genomic test may spare some patients chemotherapy

2026-08-15T00:00:00Z

De-escalation guided by gene expression in HR+ disease.

Read at Breast Cancer Research Foundation on 2026-08-15; sentiment promising.

On OnCo: Oncotype DX, HR-positive / HER2-negative breast cancer

B7-H3 ADCs gain momentum as frontline standards shift across solid tumours

2026-08-14T00:00:00Z

Ifinatamab deruxtecan and peers move toward first-line strategies.

Read at ADC Review on 2026-08-14; sentiment promising.

On OnCo: B7-H3, Ifinatamab deruxtecan, IDeate-Lung02, Small-cell lung cancer

Who decides which drug candidates move forward, and why

2026-08-14T00:00:00Z

Sector leaders argue the next decade's defining question is prioritisation, not generation, of candidates.

Read at The Cancer Letter on 2026-08-14; sentiment neutral.

On OnCo: AI-driven drug & target discovery

Accelerated approval: iberdomide + daratumumab SC + dexamethasone in myeloma

2026-08-13T00:00:00Z

The first CELMoD approval, 13 August.

Read at FDA Oncology Approvals (OCE) & Novel Drug Approvals on 2026-08-13; sentiment promising.

On OnCo: Iberdomide, Daratumumab, Multiple myeloma

PRAME-specific T-cell therapy in advanced paediatric nephroblastoma

2026-08-13T00:00:00Z

Mair et al., 13 August: TCR-directed cells against PRAME in a childhood solid tumour.

Read at New England Journal of Medicine on 2026-08-13; sentiment promising.

On OnCo: PRAME, TCR-T cell therapy

COMBI-I long-term OS: spartalizumab + dabrafenib + trametinib in BRAF V600 melanoma

2026-08-12T00:00:00Z

Ribas et al.: the triplet's long-term survival, a decade after the doublet era began.

Read at Journal of Clinical Oncology on 2026-08-12; sentiment promising.

On OnCo: Dabrafenib + trametinib, BRAF, Melanoma

Menopause and breast cancer: what you need to know

2026-08-10T00:00:00Z

Symptom-by-symptom guide to treatment-induced menopause.

Read at Living Beyond Breast Cancer on 2026-08-10; sentiment neutral.

On OnCo: Endocrine therapy (SERMs, AIs, SERDs), Supportive Care & Survivorship

FDA approves Datroway as first-line treatment for metastatic TNBC

2026-08-01T00:00:00Z

Patient explainer on the TROPION-Breast02 approval.

Read at Breast Cancer Research Foundation on 2026-08-01; sentiment promising.

On OnCo: Datopotamab deruxtecan, TROPION-Breast02, Triple-negative breast cancer (TNBC)

Pluvicto approved with an ARPI in androgen-pathway-naive or -sensitive metastatic prostate cancer

2026-07-31T00:00:00Z

PSMAddition moves radioligand therapy into hormone-sensitive disease, 31 July.

Read at FDA Oncology Approvals (OCE) & Novel Drug Approvals on 2026-07-31; sentiment promising.

On OnCo: Lutetium-177 vipivotide tetraxetan, PSMAddition, Prostate cancer, Radioligand therapy (beta emitters)

CHMP July 2026: Trodelvy indication extension recommended; catequentinib negative opinion

2026-07-24T00:00:00Z

Twelve new medicines recommended overall; one oncology extension and one sarcoma negative opinion.

Read at EMA news and CHMP meeting highlights on 2026-07-24; sentiment neutral.

On OnCo: Sacituzumab govitecan, Sarcomas (soft tissue, bone, GIST)

Oncology's next decade: the therapies and players reshaping a $400bn future

2026-07-23T00:00:00Z

Forecast to 2036: ADCs, radiopharma, bispecifics, and cell therapy drive growth.

Read at Evaluate Vantage on 2026-07-23; sentiment neutral.

On OnCo: Antibody-drug conjugate (ADC), Bispecific antibodies, Radioligand therapy (beta emitters), CAR-T cell therapy